Creating a database for patients treated with immunotherapy for solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a prospective clinic-biologic database over five years for patients undergoing immunotherapy for solid tumors. It will collect data on overall survival, progression-free survival, and responses to treatment, including adverse events associated with immunotherapy. The database will facilitate translational research to assess the effectiveness and safety of immunotherapy in real-world settings. Additionally, it will identify prognostic factors and delayed adverse events related to treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
* In neo-adjuvant, adjuvant, recurrence or metastatic situation
* Suffering from solid tumor histologically documented
* Signed written informed consent
* Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.

Exclusion Criteria:

* Pregnant or breastfeeding women
* Patient already treated by immunotherapy by immune checkpoint inhibitor
* Person under guardianship
* Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)

Where it's running

• Centre Oscar Lambret
  Lille, Hauts-de-France, France Recruiting

Study contacts

• Principal investigator: Alexandra FORESTIER, MD — Centre Oscar Lambret
• Study coordinator: Julien THERY
• Email: promotion@o-lambret.fr
• Phone: +330320295918

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer

  This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.

  Recruiting at 4 sites Phase 1/2 Hutchmed · Orange, California and 13 other locations · NCT07718581

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Personalized PULSAR radiotherapy for advanced small cell lung cancer and brain metastases

  This trial will try personalized PULSAR radiotherapy schedules to see if they are safe and helpful for adults with extensive-stage small cell lung cancer who need thoracic radiation and for adults with 1–5 brain metastases.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07139990

• VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.

  This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.

  Recruiting at 22 sites Phase 1/2 Verastem, Inc. · Los Angeles, California and 21 other locations · NCT07020221

• Using a modified cold virus to treat certain solid tumors

  This study is testing a new treatment made from a modified cold virus to see if it can safely target and help people with certain types of solid tumors.

  Recruiting at 7 sites Phase 1/2 Accession Therapeutics Limited · Barcelona and 7 other locations · NCT06977737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.